肝衰竭若干诊治要点探讨

doi:10.3969/j.issn.1672-5069.2016.03.004

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (3): 266-269.doi: 10.3969/j.issn.1672-5069.2016.03.004

肝衰竭若干诊治要点探讨

陈永平，许烂漫

325000 浙江省温州市温州医科大学附属第一医院感染病科/肝病研究所/温州市肝脏病学重点实验室/温州市重点创新团队

收稿日期:2016-04-02 出版日期:2016-05-10 发布日期:2016-05-20
作者简介:陈永平，E-mail：13505777281@163.com
基金资助:
国家自然科学基金项目（编号：81570514）；国家青年科学基金项目（编号：81500477）；浙江省自然科学基金项目（编号：LY15H030017/LQ15H030006）；温州市科技计划项目（编号：Y20150014）

Diagnosis and management of patients with hepatic failure: What's going on？

Chen Yongping，Xu Lanman

Department of Infectious Diseases，First Affiliated Hospital，Wenzhou Medical University，Wenzhou 325000，Zhejiang Province

Received:2016-04-02 Online:2016-05-10 Published:2016-05-20

摘要/Abstract

关键词: 肝衰竭, 诊断, 治疗

Key words: Hepatic failure, Diagnosis, Treatment

陈永平，许烂漫. 肝衰竭若干诊治要点探讨[J]. 实用肝脏病杂志, 2016, 19(3): 266-269.

Chen Yongping,Xu Lanman. Diagnosis and management of patients with hepatic failure: What's going on？[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 266-269.

[1] Blachier M，Leleu HM，Radosavljevic P，et al. The burden of liver disease in Europe:a review of available epidemiological data. J Hepatol，2013，58（3）:593-608.
[2] Wang X，Ning Q. Immune mediated liver failure. EXCLI
J，2014，13:1131-1144.
[3] Marra F，Aleffi S，Galastri S，et al. Mononuclear cells in liver fibrosis. Semin Immunopathol，2009，31（3）:345-358.
[4] Hammerich L，Heymann F，Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol，2011，2011:345803.
[5] Awasthi A，Kuchroo VK. Th17 cells:from precursors to players in inflammation and infection. Int Immunol，2009，21（5）: 489-498.
[6] Zhai S，Zhang L，Dang S，et al. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure. Viral Immunol， 2011，24（4）:303-310.
[7] Niu YH，Yin DL，Liu HL，et al. Restoring the Treg cell to Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure. World J Gastroenterol，2013，19（26）:4146-4154.
[8] Xu L，Gong Y，Wang B，et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis:regulation of Treg/Th17 cells. J Gastroenterol Hepatol，2014，29（8）:1620-1628.
[9] Sarin SK，Kedarisetty CK，Abbas Z，et al. Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver （APASL） 2014. Hepatol Int，2014，8（4）:453-471.
[10] Martin AP，Bartels M，Hauss J，et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc，2007，39（10）:3169-3174.
[11] Duan BW，Lu SC，Wu JS，et al. Model for end-stage liver disease（MELD） score does not predict outcomes of hepatitis B-induced acute-on-chronic liver failure in transplant recipients. Transplant Proc，2014，46（10）:3502-3506.
[12] Duseja A，Choudhary NS，Gupta S， et al. APACHE II score is superior to SOFA，CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure （ACLF）. J Dig Dis，2013，14（9）:484-490.
[13] Zheng MH，Shi KQ，Fan YC，et al. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol，2011，9（4）:351-356 e353.
[14] Zheng MH，Shi KQ，Lin XF，et al. A model to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure using artificial neural network. J Viral Hepat，2013，20（4）:248-255.
[15] Zheng MH，Wu SJ，Shi KQ，et al. Conditional survival estimate of acute-on-chronic hepatitis B liver failure:a dynamic prediction based on a multicenter cohort. Oncotarget，2015，6（27）:23261-23271.
[16] Bianchi G，Marzocchi R，Lorusso C，et al. Nutritional treatment of chronic liver failure. Hepatol Res，2008，38（ Suppl 1）:S93-S101.
[17] Chen RC，Xu LM，Du SJ，et al. Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function，balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding. Toxicol Lett，2016，241:103-110.
[18] Tsien CD，McCullough AJ，Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol，2012，27（3）:430-441.
[19] Hwang JP，Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol，2014，11（4）:209-219.
[20] Kusumoto S，Tanaka Y，Mizokami M，et al. Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy. Hepatology，2014，60（2）:765-766.
[21] Zoulim F，Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol，2008，48（Suppl 1）:S2-19.
[22] Larson AM. Diagnosis and management of acute liver failure. Curr Opin Gastroenterol，2010，26（3）:214-221.
[23] Sarin SK，Choudhury A. Acute-on-chronic liver failure: terminology，mechanisms and management. Nat Rev Gastroenterol Hepatol，2016，13（3）:131-149.
[24] Bernardi M，Ricci CS，Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol，2014，4（4）:302-311.
[25] Bernal W，Hall C，Karvellas CJ，et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology，2007，46（6）:1844-1852.
[26] Braissant O，McLin VA，Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis，2013，36（4）:595-612.
[27] Wright G，Vairappan B，Stadlbauer V，et al. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver Int，2012，32（3）:410-419.
[28] Guo LM，Liu JY，Xu DZ，et al. Application of molecular adsorbents recirculating system to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int，2003，23 （Suppl 3）:16-20.
[29] McMillin M，Frampton G，Thompson M，et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation，2014，11:121.
[30] Chen G，Shi J，Hu Z，et al. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats:a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm，2008，2008:716458.
[31] Bemeur C，Vaquero J，Desjardins P，et al. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice:antioxidant and anti-inflammatory mechanisms. Metab Brain Dis，2010，25（2）:241-249.

肝衰竭若干诊治要点探讨

Diagnosis and management of patients with hepatic failure: What's going on？

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[7]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[10]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[11]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[12]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[13]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[14]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[15]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.